Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine

Lada Leyens*, Etienne Richer, Oyvind Melien, Wolfgang Ballensiefen, Angela Brand

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Web of Science)
Original languageEnglish
Pages (from-to)249-259
JournalPublic Health Genomics
Issue number5
Publication statusPublished - 2015


  • Early patient access
  • Conditional approval
  • Accelerated approval
  • Personalized medicine
  • Drug development
  • Regulation
  • European Medicines Agency
  • Food and Drug Administration
  • Health technology assessment

Cite this